Early Life Adversity as a Risk Factor for Fibromyalgia in Later Life

Lucie A. Low and Petra Schweinhardt

Alan Edwards Centre for Research on Pain, McGill University, 3640 University Street, Montreal, QC, Canada H3A 2B2

Correspondence should be addressed to Petra Schweinhardt, petra.schweinhardt@mcgill.ca

Received 27 April 2011; Accepted 25 July 2011

Academic Editor: Charles Vierck

The impact of early life events is increasingly becoming apparent, as studies investigate how early childhood can shape long-term physiology and behaviour. Fibromyalgia (FM), which is characterised by increased pain sensitivity and a number of affective co-morbidities, has an unclear etiology. This paper discusses risk factors from early life that may increase the occurrence or severity of FM in later life: pain experience during neonatal life causes long-lasting changes in nociceptive circuitry and increases pain sensitivity in the older organism; premature birth and related stressor exposure cause lasting changes in stress responsivity; maternal deprivation affects anxiety-like behaviours that may be partially mediated by epigenetic modulation of the genome—all these adult phenotypes are strikingly similar to symptoms displayed by FM sufferers. In addition, childhood trauma and exposure to substances of abuse may cause lasting changes in developing neurotransmitter and endocrine circuits that are linked to anxiety and stress responses.

1. Introduction

The causes and underlying pathologies dictating and affecting the development of fibromyalgia (FM) are not yet clear, but as a syndrome affecting between 2 and 4% of the population, with a higher incidence in women [1, 2], it is a hot topic in pain research at this time. As discussed in detail elsewhere in this paper, FM constitutes a chronic pain syndrome, concomitant with a myriad of symptoms, including muscular stiffness and tenderness at specific locations, chronic fatigue, cognitive and mood disturbances, and insomnia. Documented pathophysiologicals related to FM include aberrations in neuroendocrine systems, dysfunction in stress regulation and neurotransmitter function, and alterations in brain structure and connectivity. In addition, FM is linked to psychosocial and environmental triggering factors. This paper will explain and discuss some of the potential risk factors of early life adversity (ELA) that display markedly similar outcomes that constitute some of the later symptoms of FM. Pain researchers have clearly shown that noxious events during early life can cause a number of long-lasting changes in pain processing systems in the older organism, which could contribute to the increased pain sensitivity noted in FM patients. In addition, factors such as premature birth and related exposure to stressors, maternal deprivation, and physical or substance abuse in the perinatal period can influence developing neurobiological and psychological states in a number of ways, often causing changes in adulthood similar to the disturbances seen in FM sufferers. Early life pain, hospitalisation, deprivation, emotional trauma, and abuse are discussed in this paper, with speculation about their potential impact upon fibromyalgia.

2. Risk Factor: Painful Experiences during Infant Development

It is well established that the experience of pain during infancy causes long-lasting alterations in pain processing that extend well into childhood and adulthood [3–5]. This adds weight to the need for effective understanding and management of pain in neonates, in order to minimise later consequences of early pain experience (see [6, 7]). Infants born with preexisting illnesses or under difficult circumstances, born preterm or needing early surgery, may all need hospitalisation for treatment. In addition, the incidence of premature birth and the necessary associated critical care has increased over the last 20 years [8], and the
technology to aid survival has meant that infants as young as 24 weeks postmenstrual age (PMA) can survive and develop on the neonatal intensive care unit (NICU). In these clinical settings, multiple painful procedures may be performed daily for routine monitoring, in addition to any necessary surgeries infants require—for example, Simons et al. [9] found that during the first 14 days of hospitalisation, neonates were subject to an average of 14 painful procedures per day. A more recent study [10] confirmed these findings, showing that neonates were exposed to a daily average of 16 painful and/or stressful procedures and that up to 80% of children were not given specific analgesia for these procedures. This high number of procedures, perhaps repeated over a number of weeks or months, affects the developing nociceptive circuitry of the infant in ways that cause long-lasting changes in pain processing (see [3]) and could explain some of the abnormalities in pain processing displayed by FM patients.

2.1. The Effect of Painful Stimulation on the Human Neonate. Studies of ex-premature children provide compelling evidence for the long-term effects of human early pain experiences. Walker et al. [11] recently presented data on sensory sensitivity in a cohort of 307 extremely preterm infants born at less than 26 weeks postmenstrual age (PMA) in 1995 and followed throughout their lives so far (the UK EPICure cohort). Quantitative sensory testing (QST) established sensory thresholds in these children at age 11 and showed that these extremely preterm children had significantly decreased sensitivity to non-noxious mechanical and thermal stimuli compared to age- and sex-matched term born controls. A similar result has been seen in 9–12-year-old children who had previously experienced neonatal cardiac surgery—subjects were significantly less sensitive to nonnoxious mechanical and thermal stimuli at both the previously operated site and noninjured areas [12]. The foundations for this baseline hyposensitivity may be laid whilst children are being cared for on the NICU—following children with NICU experience at 4, 8, and 18 months of (corrected) age, dampened pain responses to immunisation and blunted nociceptive sensitivity to everyday bumps are seen, compared to full-term controls with no NICU experience [13, 14]. Hermann et al. [15] also found elevated heat pain thresholds (i.e., decreased sensitivity) in children who had been hospitalised for a prolonged period as infants and had undergone repeated painful procedures as part of their treatment.

Importantly and more relevant to FM, when pain-exposed neonates are reexposed to noxious stimuli in later life, hypersensitivity to the stimulus is observed. For example, when ex-NICU infants were tested on their perceptual sensitisation to heat pain, where a constant temperature is given for 30 seconds and the change in perception gauged at the end, neonatally hospitalised children showed increased sensitisation compared to nonhospitalised controls, who habituated to the thermal stimulus [15]. Interestingly, heat pain thresholds of all groups of children were increased in the presence of the children’s mothers [16], highlighting the importance of social support on the pain experience (which has also been shown to be effective in alleviating the impact of FM [17]). More studies confirm the hypersensitivity seen in ex-premature infants after noxious stimulation in the older child. For example, behavioural sensitivity to noxious mechanical stimuli at the heel persists for at least the first year of life after repeated NICU heel lance experience [18]. Deep somatic and visceral noxious stimulation resulting from early invasive surgery leads to sensitisation of pain responses to later surgery, particularly in regions of the body served by the same spinal nerves as those affected by the initial surgery [19]. These effects are not limited to surgical pain. Children who suffered from burn injuries in infancy (6–18 months of age) showed lower mechanical pain thresholds and greater perceptual sensitisation to both heat and mechanical pain stimuli at sites not originally affected by the burn at ages 9–16 [20]. An interesting study by Buskila and colleagues [21] may be particularly relevant to adult fibromyalgia patients: this study showed that ex-NICU neonates had, as 12–18 year olds, significantly more “tender points” and lower tenderness thresholds than matched full-term children. Seeing as FM diagnosis has been partly based on soreness at a certain number of “tender points”, it could be informative to follow these adolescents over time and assess later FM prevalence.

Summarising the above, hypo- as well as hypersensitivity has been observed as a consequence of early life pain. The way in which sensory processing is altered by early life pain may be dependent on several factors. For example, the developmental time point at which injury is experienced can dictate the lasting effects of these injuries (see discussion of the “critical period” in the section "Early Life Exposure to Pain May Influence Fibromyalgia"). In addition, the type of noxious insult (surgical, burn, etc.) and therefore the relative proportion of nociceptors that are activated (i.e., C fibre or A delta nociceptors) may influence the exact nature of altered sensory processing. Finally, as detailed in the following section, it may be that discrete CNS systems are responsible for decreases in tactile and thermal sensitivities and the hyperalgesia seen in neonatally injured humans.

Animal models of neonatal pain show markedly similar effects as those seen in humans and are crucial to identify and understand cellular mechanisms that are impossible to study in humans. The development of nociceptive circuitry has been studied in-depth, and the neurobiology underlying long-lasting changes is becoming increasingly clear (see [3]).

2.2. The Neurobiology Underlying Long-Term Effects Can Be Studied in Animal Models. The utility of animal models is illustrated by evidence showing that the generalised hyposensitivity to mechanical and thermal stimuli shown in humans with early life pain experience (e.g., [14]) is likely mediated by changes in the brainstem regions that modulate ascending afferent input, in particular the periaqueductual grey (PAG) and rostroventral medulla (RVM), which can either enhance or suppress nociceptive input from the spinal cord [22–25]. In the rat, these areas (PAG and RVM) mature over the first three weeks of age [26–28], which corresponds approximately to the time span from the third
of the dorsal horn of the spinal cord [40]. Inflammation and concomitant release of inflammatory and trophic molecules results in enhanced spinal neuronal responses to paw pinch in the adult, as well as increased primary afferent nerve fibre innervation of the dorsal horn of the spinal cord [40]. Inflammation-induced alterations in the developmental connectivity of the spinal cord [41] and/or sprouting of nerve fibres at the skin also result in an increased nociceptive response [42]. Neonatal skin wounds, like inflammation, cause drops in mechanical withdrawal thresholds at the site of injury and increase in dorsal horn receptive field size weeks after the wound had healed [43, 44], as well as causing release of nerve growth factors leading to hyperinnervation of the skin, and increased sensitivity to noxious stimuli in later life [45]. This is consistent with human studies showing hypersensitivity after injury in children, especially those with previous surgical history [19, 46, 47]. Therefore, the apparent contradiction between generalised decreased sensitivities and hyperalgesic responses to new noxious stimulation may in part be due to discrete CNS processing systems dictating behavioural responses, for example, enhanced endogenous pain inhibition at a brainstem level, but increased hypersensitivity/hyperinnervation at a spinal level.

2.3. Early Life Exposure to Pain May Influence Fibromyalgia. As explained above, whilst La Prairie and Murphy [31] showed that animals subject to neonatal inflammation showed generalised hypoalgesia to thermal stimuli at baseline in adulthood, when animals were reinnjured as adults, animals were more sensitive to noxious thermal stimulation. Importantly, all of these effects were greatest in female animals. This finding might be relevant to fibromyalgia syndrome, as the incidence of FM is greater in women [48]. Furthermore, disturbances in descending pain modulation have been reported in FM patients [49, 50] and patients show decreased blood serum levels of serotonin and lower CSF levels of serotonin and noradrenaline metabolites [51–54]. This may be relevant to FM, as there is a discrete descending serotonergic system projecting from the RVM that modulates spinal cord excitability [55–59]. Furthermore, noradrenergic signalling, originating from the locus coeruleus, has a role centrally in feedback inhibition of pain (see [60]).

The developmental timing of any injury determines potential long-term effects, leading to the concept of a “critical period” of nociceptive development, within which pain experience permanently alters pain processing (see [5, 61]). To illustrate, giving a skin incision to the hindpaw of a neonatal rat at postnatal days (P) 3 or 6 produces an increased pain response to a repeat incision 2 weeks later. If, however, the initial incision is performed after the critical period (at P10, 21, or 40 followed by repeat incisions 2 weeks later), the enhanced hypersensitivity to the later incision is not seen [61]. Understanding the concept of a “critical period” of nociceptive development may be useful for determining some of the root causes of fibromyalgia—as human infants born prematurely display long-term alterations in pain processing, it is possible that early pain experience within this time window contributes to some of the adult pain in FM. At this time, there is very little literature that attempts to delve into the neonatal and childhood life of current FM patients.

2.4. Adequate Pain Management of Neonates May Decrease FM Prevalence in Adults. In order to prevent these physiologically disturbances, adequate pain management for human neonates is an important clinical issue. Pain management of neonates is a difficult area, as neonates cannot give verbal feedback on their pain experience, and are physiologically very different to the adult state that dictates dosage, metabolism and efficacy (i.e., [7]). Current treatments include morphine and benzodiazepines both for postsurgical pain and general sedation on the NICU [62], as well as non-pharmacological interventions such as the administration of sucrose for acute procedures including heel lance [63] (although the effectiveness of these interventions and the long-term effects of chronic exposure to sucrose and drugs such as morphine are not yet clear [64, 65]). The effects of these continue to be studied, and given the long-term effects of early pain as discussed above, adequate pain management for neonates might reduce various pain syndromes in later life, including fibromyalgia. The importance of adequate analgesia for neonatal procedures is illustrated in a seminal paper by Taddio et al. [46]. They performed a double-blind, randomized, controlled trial (RCT) on the effects of a topical anaesthetic (EMLA cream) used during male neonatal circumcision, which has traditionally been done without anaesthesia or analgesia. Looking at pain responses in the infants when they were later vaccinated at 4–6 months, boys who had been treated with the EMLA cream when circumcised showed lower pain responses than those who received no anaesthesia, and the circumcised groups both showed higher pain scores than uncircumcised controls.
3. Risk Factor: Premature Birth and Related Stressors

As discussed above, pain during the neonatal period can alter the nociceptive processing pathways of an organism for life, potentially impacting upon the development of fibromyalgia in later life. Many of the human studies mentioned in the previous section recruited infants born prematurely, needing the intensive care unit for survival. The NICU is a strange and abnormal environment in comparison to the womb, and premature infants are exposed to many stressful stimuli in addition to repeated nociceptive procedures, such as light, noise, tactile stimulation, surgery, medication, and maternal separation, all of which could feasibly affect development [66]. Indeed, even the act of nursing very premature infants (changing diapers etc.) causes increases in stress hormones [67]. In addition to the long-term effects of increased pain sensitivity in these children are effects upon stress regulatory systems, where a large body of evidence suggests that prematurity and the resulting experiences on the NICU can permanently alter in particular the hypothalamic-pituitary-adrenal (HPA) axis. As this is shown to be disturbed in FM patients [68–71], it is possible to speculate that premature birth in itself may influence the occurrence of FM in adults.

3.1. Premature Birth Impacts upon the Body’s Response to Stressors. The HPA axis is the body’s stress-response system. Cells of the hypothalamus produce corticotropin-releasing factor (CRF) in response to an environmental stressor, and a cascade of events ultimately causes adrenaline release and the production of the “stress hormone” cortisol. Under normal circumstances, adrenaline and cortisol release is terminated via a negative feedback circuit. In FM, however, HPA axis regulation appears to be abnormal. Whilst the precise dysfunctions in stress regulation via the HPA axis are not clear at this point (some studies find FM patients show hypocortisolism (see [72])), whilst others describe hypercortisolism and HPA hyperactivity [68, 69, 73]), what is clear is that HPA axis function is not normal in many patients. The discrepancy between findings of hyper- and hypocortisolism may be due to a number of factors. For example, disease-specific patient characteristics, such as symptom profiles and comorbidities, as well as disease-nonspecific characteristics, such as age, gender, personality traits, and socioeconomic background, can affect results. In addition, markers of HPA axis function differ between studies (e.g., basal levels or evoked cortisol responses) as do the time points of measurement (e.g., upon waking or following diurnal fluctuations), in addition to other technical details. In instances where the literature does not permit any conclusions on the direction, we refer to alterations in HPA axis function, rather than increases or decreases.

Nevertheless, the way in which premature birth alters cortisol levels and cortisol responses compared to term-born controls is relatively unambiguous. Grunau et al. [66] propose that early stressors such as those routinely experienced in the NICU can impact upon development of the HPA axis by causing consistent release of adrenaline and cortisol and increase the “allostatic load” of the neonate—the concept of “allostasis” explaining how an organism’s physiological systems fluctuate over time in order to meet the demands of external stressors, in an attempt to regain homeostasis (bodily equilibrium). The impact of chronic stress and the accompanying neuroendocrine responses may also ultimately cause long-lasting damage to bodily organs and contribute to chronic disease development [74]. In preterm neonates, this may manifest as a life-long shift in HPA axis balance.

Basal cortisol levels are often low in neonates on the NICU in comparison to term infants, which is unexpected considering the length of time that infants spend there and the stressful procedures the still-developing neonate is subject to [75, 76]. Grunau and colleagues have published a series of studies giving convincing evidence that NICU experience causes “resetting” of the endocrine stress systems, by measuring cortisol levels after noxious experiences in ex-preterm infants, either whilst still on the NICU (short-term effects), or in the months to years following. When a clinically required heel lance was done whilst infants were still on the NICU, the earliest premature infants born at less than 28 weeks gestational age (i.e., approximately 3 months premature) showed a dampened cortisol response to heel lance. In addition, higher cumulative exposure to neonatal procedural pain over the length of stay in the NICU was related to lower cortisol release to standard nursing procedures [77]. When immunised at 2–4 months (corrected) age, low gestation age (LGA) boys (<32 weeks), but not girls, showed lower cortisol concentrations than full-term infants after injections, although facial and heart rate responses did not differ between groups [78].

When studied over a longer period of time, we see that this early dampened cortisol response in premature infants changes to elevations in cortisol levels and responses when the children are older. At 8 months old, infants born at extremely low gestational age (≤28 weeks) with previously low basal cortisol levels, showed elevated basal levels as well as greater increases in cortisol response to stressors, compared to term infants. In these children, greater increases in cortisol were associated with higher numbers of skin-breaking procedures experienced in the past on the NICU [79]. Grunau et al. [80] followed the time course of this “switch” from low to high stress hormone levels and found that at 3 months corrected age, basal cortisol levels were lower than term controls, but, at 8 and 18 months, the youngest ex-premature infants had significantly higher cortisol levels than term controls. The authors speculate that the HPA axis has been “reprogrammed” by NICU experience. Recent work has replicated the finding that premature children born onto the NICU later have higher basal cortisol levels compared to term-born controls at both 18 months [81] and upon waking in 8–14 year old ex-premature infants [82].

Animal studies support the existence of a developmental shift from low to high cortisol levels after perinatal corticosteroid exposure, and these higher levels of cortisol seen in older animals are associated with increased levels
of corticotropin-releasing hormone (CRH) mRNA and glucocorticoid (GC) receptors in the amygdala (e.g., [83, 84]). In humans, this shift from low to high levels over development may be influenced by the fact that the mothers at risk of giving birth prematurely are routinely given corticosteroids to delay birth and enhance infant survival and lung function—an intervention which suppresses cortisol secretion in the infant when born [85] yet causes an increased cortisol response after heel lance at 24 hours after birth [86]. Further work is needed to address the impact of perinatal glucocorticoid exposure on the stress response axis in later life.

3.2. Prematurity May Contribute to Adult FM Symptoms via the HPA Axis. The above evidence highlights how premature birth and the stressors associated with it can influence the physiological response to stress and “reset” the balance of the HPA axis response. Seeing as FM patients routinely show imbalances in the stress response, it is reasonable to hypothesise that premature birth may be a risk factor for developing FM in later life. Indeed, Klingmann et al. [87] show that of 93 female FM patients, 62% reported a gestation length of <38 weeks, which was related to a lower cortisol response upon waking when compared to full-term FM patients. The authors speculate that enhanced glucocorticoid levels in the mother during pregnancy or in response to premature birth affect the development of the adrenal glands in the foetus/premature infant, rendering the HPA axis less capable of dampening stress responses to later stressors. This in turn may disinhibit responses to physical or psychological stress and affect brain function, resulting in enhanced responses to pain and increased fatigue levels. Support for this hypothesis comes from animal studies of prenatal glucocorticoid exposure, where dam rats are exposed to substances that increase HPA axis activity (such as glucocorticoid receptor agonists), in the third trimester of gestation. Results show that the adrenal glands and brain weight of the adult offspring are smaller, stress regulation is compromised, and cognitive dysfunction is seen in tests of memory as well as anxiety-like behaviour, with the effects exacerbated in female offspring [88–93].

3.3. Cognitive Symptoms of FM May Arise from Differences in Brain Development Caused by Premature Birth. One symptom of FM, colloquially called “fibro-fog” by sufferers, constitutes cognitive deficits, with patients complaining of difficulties in memory and attention that mimic the effects of an extra 20 years of ageing (e.g., [94, 95]). Additional evidence that prematurity may influence the development of FM comes from studies showing that the risks of cognitive and psychiatric impairment are much greater in ex-preterm infants. The EPICure cohorts (born at ≤25 weeks gestation) have recently had their cognitive abilities and psychiatric profiles investigated at 11 years of age. Results showed that the children born at the youngest preterm ages are at higher risk of ADHD, autism spectrum, and emotional disorders [96] and show increased incidences of learning impairments and poor academic attainment [97]. Other meta-analyses and epidemiological studies have confirmed the increased risk for psychiatric symptoms and poorer academic performance in older childhood after premature birth [98–100].

Brain imaging of ex-preterm infants compared to full-term controls has shown underlying changes in brain structure and function that may help explain some of these deficits. Cortical surface area is decreased at full-term in extremely preterm infants [101], and the incidence of white matter abnormalities persisting past 18 months (corrected) age is increased [102]. Thalamic volume is also reduced in preterm children at term-equivalent age [103] and at 2 years of age, and connectivity between the thalamus and cortex may be disrupted in ex-preterm children [104]. Seeing as the premature brain is still developing at a rapid pace and as myelination occurs during late preterm maturation [105], it is likely that prematurity influences white matter development, helping to explain why later cognitive deficits may arise. If premature birth becomes a proven risk factor for fibromyalgia, the neural bases of “fibro-fog” may become better understood in the adult.

4. Risk Factor: Maternal Deprivation

As discussed above, early pain experience and prematurity may be risk factors for FM development in later life. Prematurity might be a risk factor in combination with the high exposure to additional stressors, including maternal deprivation. Relatively detailed information is available on the effects of maternal deprivation on the developing organism, and therefore maternal deprivation is discussed separately. Animal models of deprivation have proven extremely useful in illustrating the effects of deprivation from the primary caregiver (generally the mother) and the strong role for the fluidity of genetic expression during early life in the shaping of the adult phenotype. The study of epigenetics, or how the environment influences the activation and expression of different genes, has provided fascinating insights into this fluidity.

4.1. Maternal Deprivation in Animal Models Influences Later Stress Responses. Animal models of maternal deprivation often use rats and generally employ a paradigm whereby pups are separated from the mother for at least an hour per day, much longer than the 20–25 minutes of absence that dam (mother) rats are routinely away from the nest [106]. When neonatal rats are exposed to these prolonged periods of deprivation during the first weeks of life, a number of physiological and behavioural changes occur in the adult animal. For example, rats separated from the dam for 180 minutes per day from postnatal day (P) 2–14 show elevated levels of CRF mRNA as adults, which causes adrenaline and cortisol release via activation of the HPA axis [107, 108]. They also show more anxiety-like behaviours as adults and an increased propensity to consume alcohol [109, 110]. Accordingly, maternal deprivation has now been used to model various psychiatric states such as anxiety [111], addictive disorders [112], and schizophrenia [113], and a recent study by Uhelski and Fuchs [114]
showed that maternally deprived animals showed increased active avoidance of environments in which pain had been experienced, suggesting enhanced supraspinally mediated responses to pain. The importance of maternal presence is further illustrated by work with monkeys: infants reared in the absence of an adult caregiver but together with age-matched peers develop chronic anxiety-like behaviours and disordered cortisol levels to stressors (suggesting HPA axis imbalance), similar to FM symptoms [115]. Taken together, these data show that maternal deprivation has been associated with three important disturbances found among FM patients, namely, alterations in the HPA axis, increased anxiety, and increased pain responses [116].

Short-term separation of pups conversely causes opposite effects to longer maternal deprivation. If pups are subject to only 15 minutes of deprivation, the adult animals display more social contact and better stress-coping abilities compared to animals deprived for longer periods [117–121]. These effects seem to be mediated by the maternal style of the dam upon reunion with the pups—mothers of pups separated for short periods engage in more licking/grooming and arched-back nursing (LG-ABN) when reunited compared to dams of pups separated for more prolonged periods. Dams that engage in high levels of this nursing style produce offspring that show more efficient stress regulation, as measured by corticosterone (the animal equivalent of CRH) responses to stress and feedback sensitivity of the HPA axis [122, 123]. In fact, the maternal LG-ABN style (either high or low) causes individual differences in stress responsiveness and emotionality that remain stable in the adult offspring [124] and is in itself a trait that is passed on to female offspring. Cross-fostering studies, where pups from low or high LG-ABN dams are reared by dams showing the opposite LG-ABN behaviour illustrate that female offspring will show nursing styles akin to their “foster” dam rather than their biological dam [125]. Further evidence for the fluidity of these behavioural phenotypes comes from evidence that low LG-ABM dams rearing litters in a socially-enriched environment produce offspring showing enhanced exploration and licking/grooming behaviour of their own offspring [126].

The effects upon adult phenotype that depend on maternal style are regulated by changes in DNA methylation of the infant genome, leading to activation or silencing of certain genes, and alterations in levels of, for example, glucocorticoid receptors [122], neurotrophic factors and specific neurotransmitter receptors in the hippocampus [127]. Serotonin (5-HT) turnover (as seen by measures of 5-HT levels compared to levels of 5-HT metabolites) is also increased in maternally deprived animals [128], and expression and levels of serotonin receptors and transporter proteins altered [129, 130]. This is particularly relevant to FM, as the serotonergic system has been implicated in the affective components associated with FM—cerebrospinal fluid levels of 5-HT metabolites are decreased in patients [53], serotonin antagonists are effective drugs for some FM patients with no associated depressive comorbidities [131], and increased incidence of a specific genetic polymorphism in the 5-HT transporter gene has been identified in FM patients [132], although the exact disorders in serotonergic signalling are not yet clear [133]. However, some of the heterogeneity in FM patients may arise due to epigenetic alterations that occurred during early infancy. To date, no research has been conducted on this specific question.

4.2. Quality of Maternal Attachment Affects Pain Processing. The quality of the relationship between child and primary caregiver (generally the mother) can also dictate emotional reactivity throughout life and the type of attachment style that an individual will form with others throughout their life. Bowlby first developed the idea of “attachment theory”, studying the bond between child and mother and suggested that a secure attachment style is the most beneficial for infant development [134, 135]. Since then, studies have shown that disordered attachment styles are linked to chronic pain and problems coping with pain (see [136]). For example, chronic pain patients with high levels of avoidant attachment self-scored pain intensity more highly, and patients with fearful attachment styles display increased levels of pain catastrophising, linked to anxiety levels [137, 138]. In acute pain tests, adults showing secure attachment styles rated pain as less intense and anxiogenic [139]. Importantly for FM, secure attachment formation is linked to the dopamine and opioiergic system in both animals and humans [140, 141], suggesting that a secure early attachment between infant and parent could be protective against developing FM in later life. Hallberg and Carlsson [142] indeed mention the overrepresentation of individuals with insecure attachment styles in the chronic pain patient population.

5. Risk Factor: Childhood Physical and Psychological Trauma

Physical and sexual abuse during childhood are well-documented risk factors in the development of fibromyalgia [143–146], and two recent meta-analyses link childhood incidence of physical and sexual abuse with FM [147, 148]. Early life abuse carries with it the burden of a number of other behavioural and pathological problems, including increased incidence of depression, posttraumatic stress disorder, alcoholism, substance abuse, obesity, ill health, and suicide ([149; see 150]). A number of these are also comorbidities in FM. It is possible that the impact of early abuse and trauma contributes to FM via disruption of neurotransmitter systems such as the serotonergic and dopaminergic systems and impacts stress-management via the HPA axis [151–155].

5.1. A High Incidence of Childhood Abuse Is Reported in FM Patients. Self-report studies, where patients are questioned on their childhood history, consistently show increased early life adversity in FM patients. Goldberg et al. [156] found that three different groups of chronic pain patients (facial pain, myofascial pain, and FM), all had a history of abuse in nearly 50% of cases, rising to 65% in the fibromyalgia group. In particular, females with an alcoholic parent were likely to be members of the FM group. Hallberg and Carlsson [142] conducted in-depth interviews with 22 FM patients
and describe “abundant examples of early loss (and...) high degree of responsibility early in life,” and Anderberg et al. [157] found that, of 40 female FM patients, 51% had experienced very negative childhood or adolescence life events, compared to 28% in healthy age-matched women. Nicolson et al. [158] found an association of self-reported childhood abuse and neglect with FM patients’ daily cortisol levels, finding the most disordered cortisol responses in the patients reporting the highest levels of sexual and emotional abuse. This suggests that early abuse further impacts upon the HPA axis, which shows aberrant functionality in FM in abuse. This suggests that early abuse further impacts upon the HPA axis, which shows aberrant functionality in FM in patients with no history of abuse [71]. Childhood rape has also been strongly associated with a lifetime diagnosis of FM [147].

The loss of a parent during early childhood is an emotionally traumatic event and is associated with altered daily cortisol levels in the adult, particularly in men [159, 160]. Poor quality family relationships during childhood also cause changes in cortisol release in response to a stressful event [161]. In addition, early-life stress and trauma has been shown to be a significant predictor of levels of CRF in cerebrospinal fluid (CSF) in non-FM subjects [162], and Danese et al. [163] found an association between early-life maltreatment and adult blood levels of C-reactive protein, a marker of inflammation. Specific to fibromyalgia, McLean et al. [164] showed that women with FM who reported sexual or physical abuse in their personal histories had differences in CSF levels of CRF compared to nonabused FM women, and Weissbecker and colleagues [165] found that a similar group of FM women abused in childhood had disordered diurnal cortisol levels.

However, studies based on the self-report of FM patients can be difficult to verify. Adult life experiences may bias memories from early life, and it is possible that FM patients, due to their current pain and comorbid states, become self-centred and preoccupied with the pain, and potentially overemphasise traumatic memories [166, 167]. Longitudinal studies following children and young people who have suffered from documented abuse, for example, children in social care, would be useful in order to avoid this confound. Epidemiological studies of socioeconomic position (SEP) during childhood have shown that lower SEP during childhood is a predictor of chronic widespread pain in later life [168]. Whilst socioeconomic status incorporates a large number of factors, trauma-related hospitalisations are more prevalent in children from lower socioeconomic statuses who have less access to appropriate healthcare [169–172].

6. Risk Factor: Perinatal Exposure to Substances of Abuse

Serotonin is not the only neurotransmitter system altered in fibromyalgia—dopamine and opioid neurotransmitter disturbances are also reported that may, in part, result from interference with these developing systems during pre- or early postnatal life. Dopamine responses of FM patients to painful stimuli are lower than those of healthy subjects [173], and low CSF levels of dopamine (as well as serotonin and norepinephrine) metabolites are seen in patients [52]. Furthermore, the opioid system is closely linked to dopaminergic signalling, constitutes an important endogenous antinociceptive system, and is altered in FM [174, 175]. Exposure to a number of substances during early life will impact upon the development of these neurotransmitter systems. For example, exposure of the foetus to alcohol induces dysfunction in dopaminergic and serotonergic systems and will persistently affect the development of the HPA axis [176–178], all of which are, as mentioned, disturbed in FM.

6.1. Early Opioid Exposure Causes Long-Lasting Changes in Nociceptive Systems. Early exposure to opioids, such as exposure of the foetus to heroin or methadone during pregnancy, or prolonged morphine administration after birth, for example, on the NICU, causes lasting changes in opioid signalling. If exposure occurs prenatally, it can result in the newly born infant undergoing withdrawal symptoms very soon after birth, the so-called neonatal abstinence syndrome (NAS) [179]—an effect mirrored in animal models of early drug dependence [180]. Morphine is used in the NICU to provide sedation in neonates requiring mechanical ventilation and to improve tolerance of ventilation and comfort of the infant. The lasting effects of this are not yet well-characterised [65, 181], although it is known that chronic morphine administration causes changes in mu-opioid receptor density and sensitivity that desensitises older animals to opiate analgesia [182, 183]. As the opioidergic and dopaminergic systems are crucial for endogenous modulation of pain, and this modulation seems to be disordered in fibromyalgia, longitudinal studies of early life exposure to opioids may help explain some of the disturbances in opioid function seen in FM. Positron emission tomography (PET) studies would be useful to investigate if the altered opioid receptor activity seen in FM patients is related to early life opioid exposure. Harris and colleagues [175, 184] have shown that FM patients show alterations in mu-opioid receptor availability, but a history of opioid use was one of the exclusion criterion for these studies, meaning that the impact of early life exposure to opioids is not yet known in terms of later FM prevalence.

6.2. Dopamine Overexposure during Early Life Affects HPA Axis Function, and May Be Mediated by Epigenetic Factors. Dopaminergic drugs such as cocaine and amphetamine increase anxiety-like behaviours in animal models of abuse during pregnancy [185], and cocaine activates the HPA axis by potentiating adrenocorticotropic hormone (ACTH) release, which in turn stimulates the adrenal glands to produce adrenaline and cortisol [186]. Increasing evidence now suggests that prenatal exposure to drugs of abuse (including alcohol, cocaine, and amphetamine) may be toxic to developing dopamine-rich areas such as the basal ganglia (see [187]). After birth, studies on the development of the dopamine system suggest that functional connectivity in the young animal, particularly to frontal cortical areas, is not mature until adolescence or later [188, 189], and it is...
levels, pain, or maternal deprivation may also partially explain the “fibrofog” and anxiety disorders prevalent in FM. Furthermore, impairments in stress regulation caused by glucocorticoids during critical periods of development may affect the body’s stress regulatory systems in the older organism, so again considering that epigenetic effects impact upon stress regulation may be more prevalent in FM. However, there is little evidence to conclusively link the two, for example, by proving that maternal deprivation or increased stress during pregnancy increases the incidence of FM.

This paper has focused on the evidence showing that painful procedures during early life cause long-lasting changes in pain processing and suggests that high exposure to painful experiences in early life may partially explain the increased pain sensitivity shown by FM patients. In addition, childhood adversities and maternal deprivation are also discussed in terms of the effects they have on stress-regulatory systems in the older organism, so again they are potentially sources of the disorders in cortisol levels and stress response seen in FM patients. As previously mentioned, the precise dysfunctions in stress regulation via the HPA axis are not yet clear in FM patients, but what is clear is that the body’s stress regulatory systems are compromised, and it is possible that the precise nature and combination of each individual’s childhood experience may be contributing to the overall symptomatology of FM.

Exposure of the developing brain to perinatal stress and glucocorticoids during critical periods of development may affect the long-term function of areas involved in stress regulation such as the hippocampus and amygdala and help explain the “fibrofog” and anxiety disorders prevalent in FM. Furthermore, impairments in stress regulation caused by early exposure to stressors such as increased maternal cortisol levels, pain, or maternal deprivation may also partially explain the increased pain sensitivities seen in FM patients. Finally, as pain is itself a stressor, the pain experienced by FM patients may be acting in a positive feedback manner to further increase anxiety levels and impact upon stress regulation. Whilst FM is unlikely to be due to a single factor, it is possible that the factors outlined in this paper, concomitant with a number of other factors such as a genetic predisposition to enhanced pain sensitivity, stressful life experiences in adult life, and the influence of sex hormones, may combine or interact to create a phenotype at higher risk of developing this form of chronic pain. Teasing apart potential influences and their mechanisms may help treat sufferers or, in fact, decrease the risk of future suffering.

References

[1] F. Wolfe, K. Ross, J. Anderson, I. J. Russell, and L. Hebert, “The prevalence and characteristics of fibromyalgia in the general population,” Arthritis and Rheumatism, vol. 38, no. 1, pp. 19–28, 1995.
[2] D. J. Clauw and L. J. Crofford, “Chronic widespread pain and fibromyalgia: what we know, and what we need to know,” Best Practice and Research, vol. 17, no. 4, pp. 685–701, 2003.
[3] M. Fitzgerald, “The development of nociceptive circuits,” Nature Reviews Neuroscience, vol. 6, no. 7, pp. 507–520, 2005.
[4] M. Fitzgerald and S. M. Walker, "Infant pain management: a developmental neurobiological approach," Nature Clinical Practice Neurology, vol. 5, no. 1, pp. 35–50, 2009.
[5] J. L. La Prairie and A. Z. Murphy, "Long-term impact of neonatal injury in male and female rats: sex differences, mechanisms and clinical implications," Frontiers in Neuroendocrinology, vol. 31, no. 2, pp. 193–202, 2010.
[6] R. F. Howard, “Current status of pain management in children,” Journal of the American Medical Association, vol. 290, no. 18, pp. 2464–2469, 2003.
[7] S. M. Walker, “Pain in children: recent advances and ongoing challenges,” British Journal of Anaesthesia, vol. 101, no. 1, pp. 101–110, 2008.
[8] J. Langhoff-Roos, U. Kesmodel, B. Jacobsson, S. Rasmussen, and I. Vogel, “Spontaneous preterm delivery in primiparous women at low risk in Denmark: population based study,” British Medical Journal, vol. 332, no. 7547, pp. 937–939, 2006.
[9] S. H. P. Simons, M. Van Dijk, K. S. Anand, D. Roothofhoof, R. A. Van Lingen, and D. Tibboel, “Do we still hurt newborn babies? A prospective study of procedural pain and analgesia in neonates,” Archives of Pediatrics and Adolescent Medicine, vol. 157, no. 11, pp. 1058–1064, 2003.
[10] R. Carbajal, A. Roussel, C. Danan et al., “Epidemiology and treatment of painful procedures in neonates in intensive care units,” Journal of the American Medical Association, vol. 300, no. 1, pp. 60–70, 2008.
[11] S. M. Walker, L. S. Franck, M. Fitzgerald, J. Myles, J. Stocks, and N. Marlow, “Long-term impact of neonatal intensive care and surgery on somatosensory perception in children born extremely preterm,” Pain, vol. 141, no. 1-2, pp. 79–87, 2009.
[12] B. M. Schmelzle-Lubeck, K. A. A. Campbell, R. H. Howard, L. Franck, and M. Fitzgerald, "Long-term consequences of early infant injury and trauma upon somatosensory
processing,” European Journal of Pain, vol. 11, no. 7, pp. 799–809, 2007.

[13] T. E. Oberlander, R. E. Grunau, M. F. Whitfield, C. Fitzgerald, S. Pitfield, and J. P. Saul, “Biobehavioral pain responses in former extremely low birth weight infants at four months’ corrected age,” Pediatrics, vol. 105, no. 1, article e6, 2000.

[14] R. V. E. Grunau, M. F. Whitfield, and J. H. Petrie, “Pain sensitivity and temperament in extremely low-birth-weight premature toddlers and preterm and full-term controls,” Pain, vol. 58, no. 3, pp. 341–346, 1994.

[15] C. Hermann, J. Hohmeister, S. Demirakca, K. Zohsel, and H. Flor, “Long-term alteration of pain sensitivity in school-aged children with early pain experiences,” Pain, vol. 125, no. 3, pp. 278–285, 2006.

[16] J. Hohmeister, S. Demirakca, K. Zohsel, H. Flor, and C. Hermann, “Responses to pain in school-aged children with experience in a neonatal intensive care unit: cognitive aspects and maternal influences,” European Journal of Pain, vol. 13, no. 1, pp. 94–101, 2009.

[17] A. Boehm, E. Eisenberg, and S. Lampel, “The contribution of social capital and coping strategies to functioning and quality of life of patients with fibromyalgia,” The Clinical Journal of Pain, vol. 27, pp. 233–239, 2011.

[18] H. M. Abdulkader, Y. Freer, E. M. Garry, S. M. Fleetwood-Walker, and N. McIntosh, “Prematurity and neonatal noxious events exert lasting effects on infant pain behaviour,” Early Human Development, vol. 84, no. 6, pp. 351–355, 2008.

[19] J. W. B. Peters, R. Schouw, K. J. S. Anand, M. Van Dijk, H. J. Duivenvoorden, and D. Tibboel, “Does neonatal surgery lead to increased pain sensitivity in later childhood?” Pain, vol. 114, no. 3, pp. 444–454, 2005.

[20] I. Wollgarten-Hadamek, J. Hohmeister, S. Demirakca, K. Zohsel, H. Flor, and C. Hermann, “Do burn injuries during infancy affect pain and sensory sensitivity in later childhood?” Pain, vol. 141, no. 1–2, pp. 165–172, 2009.

[21] D. Buskila, L. Neumann, E. Zmora, M. Feldman, A. Bolotin, and J. Press, “Pain sensitivity in prematurely born adolescents,” Archives of Pediatrics and Adolescent Medicine, vol. 157, no. 11, pp. 1079–1082, 2003.

[22] M. M. Heinricher and K. Drasner, “Lumbar intrathecal morphine alters activity of putative nociceptive modulatory neurons in rostral ventromedial medulla,” Brain Research, vol. 549, no. 2, pp. 338–341, 1991.

[23] H. L. Fields and A. I. Basbaum, “Brainstem control of spinal pain-transmission neurons,” Annual Review of Physiology, vol. 40, pp. 217–248, 1978.

[24] A. I. Basbaum and H. L. Fields, “Endogenous pain control mechanisms: review and hypothesis,” Annals of Neurology, vol. 4, no. 5, pp. 451–462, 1978.

[25] M. M. Heinricher, N. M. Barbaro, and H. L. Fields, “Putative nociceptive modulating neurons in the rostral ventromedial medulla of the rat: firing of on- and off-cells is related to nociceptive responsiveness,” Somatosensory and Motor Research, vol. 6, no. 4, pp. 427–439, 1989.

[26] T. Boucher, E. Jennings, and M. Fitzgerald, “The onset of diffuse noxious inhibitory controls in postnatal rat pups: a c-fos study,” Neuroscience Letters, vol. 257, no. 1, pp. 9–12, 1998.

[27] H. Van Praag and H. Frenk, “The development of stimulation-produced analgesia (SPA) in the rat,” Developmental Brain Research, vol. 64, no. 1–2, pp. 71–76, 1991.

[28] G. J. Hathway, S. Koch, L. Low, and M. Fitzgerald, “The changing balance of brainstem-spinal cord modulation of pain processing over the first weeks of rat postnatal life,” Journal of Physiology, vol. 587, no. 12, pp. 2927–2935, 2009.

[29] B. Clancy, B. L. Finlay, R. B. Darlington, and K. J. S. Anand, “Extrapolating brain development from experimental species to humans,” NeuroToxicology, vol. 28, no. 5, pp. 931–937, 2007.

[30] B. Clancy, B. Kersh, J. Hyde, R. B. Darlington, K. J. S. Anand, and B. L. Finlay, “Web-based method for translating neurodevelopment from laboratory species to humans,” Neuroinformatics, vol. 5, no. 1, pp. 79–94, 2007.

[31] J. L. La Prairie and A. Z. Murphy, “Female rats are more vulnerable to the long-term consequences of neonatal inflammatory injury,” Pain, vol. 132, supplement 1, pp. S124–S133, 2007.

[32] J. L. La Prairie and A. Z. Murphy, “Neonatal injury alters adult pain sensitivity by increasing opioid tone in the periaqueductal gray,” Frontiers in Behavioral Neuroscience, vol. 3, article 31, 2009.

[33] A. J. McDermid, G. B. Rollman, and G. A. McCain, “Generalized hypervigilance in fibromyalgia: evidence of perceptual amplification,” Pain, vol. 66, no. 2–3, pp. 133–144, 1996.

[34] R. Staud, C. J. Vierck, R. L. Cannon, A. P. Mauderli, and D. D. Price, “Abnormal sensitization and temporal summation of second pain (wind-up) in patients with fibromyalgia syndrome,” Pain, vol. 91, no. 1–2, pp. 165–175, 2001.

[35] R. H. Gracey, F. Petzke, J. M. Wolf, and D. J. Clauw, “Functional magnetic resonance imaging evidence of augmented pain processing in fibromyalgia,” Arthritis and Rheumatism, vol. 46, no. 5, pp. 1333–1343, 2002.

[36] F. Petzke, D. J. Clauw, K. Ambrose, A. Khine, and R. H. Gracey, “Increased pain sensitivity in fibromyalgia: effects of stimulus type and mode of presentation,” Pain, vol. 105, no. 3, pp. 403–413, 2003.

[37] K. J. S. Anand, V. Coskun, K. V. Thriivikraman, C. B. Nemerooff, and P. M. Plotsky, “Long-term behavioral effects of repetitive pain in neonatal rat pups,” Physiology and Behavior, vol. 66, no. 4, pp. 627–637, 1999.

[38] S. M. Walker, J. Meredith-Middleton, C. Cooke-Yarnborough, and M. Fitzgerald, “Neonatal inflammation and primary afferent terminal plasticity in the rat dorsal horn,” Pain, vol. 105, no. 1–2, pp. 185–195, 2003.

[39] M. S. Lidow, Z. M. Song, and K. Ren, “Long-term effects of short-lasting early local inflammatory insult,” NeuroReport, vol. 12, no. 2, pp. 399–403, 2001.

[40] M. A. Ruda, Q. D. Ling, A. G. Hohmann, Y. B. Peng, and T. Tachibana, “Altered nociceptive neuronal circuits after neonatal peripheral inflammation,” Science, vol. 289, no. 5479, pp. 628–630, 2000.

[41] S. M. Walker, J. Meredith-Middleton, C. Cooke-Yarborough, and M. Fitzgerald, “Neonatal inflammation and primary afferent terminal plasticity in the rat dorsal horn,” Pain, vol. 105, no. 1–2, pp. 185–195, 2003.

[42] K. Ren, V. Anseloni, S. P. Zou et al., “Characterization of basal and re-inflammation-associated long-term alteration in pain responsivity following short-lasting neonatal local inflammatory insult,” Pain, vol. 110, no. 3, pp. 588–596, 2004.

[43] M. L. Reynolds and M. Fitzgerald, “Long-term sensory hyperinnervation following neonatal skin wounds,” Journal of Comparative Neurology, vol. 358, no. 4, pp. 487–498, 1995.
[44] C. Torsney and M. Fitzgerald, "Spinal dorsal horn cell receptive field size is increased in adult rats following neonatal hindpaw skin injury," *Journal of Physiology*, vol. 550, no. 1, pp. 255–261, 2003.

[45] J. De Lima, D. Alvares, D. J. Hatch, and M. Fitzgerald, "Sensory hyperinnervation after neonatal skin wounding: effect of bupivacaine sciatric nerve block," *British Journal of Anaesthesia*, vol. 83, no. 4, pp. 662–664, 1999.

[46] A. Taddio, J. Katz, A. L. Illersich, and G. Koren, "Effect of neonatal circumcision on pain response during subsequent routine vaccination," *The Lancet*, vol. 349, no. 9052, pp. 599–603, 1997.

[47] K. Andrews and M. Fitzgerald, "Wound sensitivity as a measure of analgesic effects following surgery in human neonates and infants," *Pain*, vol. 99, no. 1-2, pp. 185–195, 2002.

[48] F. Wolfe, K. Ross, J. Anderson, and I. J. Russell, "Aspects of fibromyalgia in the general population: sex, pain threshold, and fibromyalgia symptoms," *Journal of Rheumatology*, vol. 22, no. 1, pp. 151–156, 1995.

[49] N. Julien, P. Goffaux, P. Arsenault, and S. Marchand, "Widespread pain in fibromyalgia is related to a deficit of endogenous pain inhibition," *Pain*, vol. 114, no. 1-2, pp. 295–302, 2005.

[50] E. Normand, S. Potvin, I. Gaumond, G. Cloutier, J.-F. Corbin, and O. Spreux-Varoquaux et al., "Platelet 3H-imipramine uptake receptor density and serum serotonin levels in patients with fibromyalgia/fibrositis syndrome," *Journal of Rheumatology*, vol. 19, no. 1, pp. 104–109, 1992.

[51] I. J. Russell, J. E. Michalek, G. A. Vipraio, E. M. Fletcher, M. A. Javors, and C. A. Bowden, "Platelet 3H-imipramine uptake receptor density and serum serotonin levels in patients with fibromyalgia/fibrositis syndrome," *Journal of Rheumatology*, vol. 19, no. 1, pp. 104–109, 1992.

[52] I. J. Russell, H. Vaeroy, M. Javors, and F. Nyberg, "Cerebrospinal fluid biogenic amine metabolites in fibromyalgia/fibrositis syndrome and rheumatoid arthritis," *Arthritis and Rheumatism*, vol. 35, no. 5, pp. 550–556, 1992.

[53] E. Legangneux, J. J. Mora, O. Spreux-Varoquaux et al., "Cerebrospinal fluid biogenic amine metabolites, plasma-rich platelet serotonin and [3H]imipramine reuptake in the primary fibromyalgia syndrome," *Rheumatology*, vol. 40, no. 3, pp. 290–296, 2001.

[54] K. C. Light, E. E. Bradlon, K. M. Grewen, K. A. Brownley, S. S. Girdler, and W. Maixner, "Adrenergic dysregulation and pain with and without acute beta-blockade in women with fibromyalgia and temporomandibular disorder," *Journal of Pain*, vol. 10, no. 5, pp. 542–552, 2009.

[55] A. H. Dickenson, J. P. Rivot, and A. Chaouch, "Diffuse noxious inhibitory controls (DNIC) in the rat with or without pCPA pretreatment," *Brain Research*, vol. 216, no. 2, pp. 313–321, 1981.

[56] N. El-Yassin and S. M. Fleetwood-Walker, "A 5-HT1-type receptor mediates the antinociceptive effect of nucleus raphe magnus stimulation in the rat," *Brain Research*, vol. 523, no. 1, pp. 92–99, 1990.

[57] T. J. Grudt, J. T. Williams, and R. A. Travagli, "Inhibition by 5-hydroxytryptamine and noradrenaline in substantia gelatinosa of guinea-pig spinal trigeminal nucleus," *Journal of Physiology*, vol. 485, no. 1, pp. 113–120, 1995.

[58] R. Suzuki, S. Morcuende, M. Webber, S. P. Hunt, and A. H. Dickenson, "Superficial NK1-expressing neurons control spinal excitability through activation of descending pathways," *Nature Neuroscience*, vol. 5, no. 12, pp. 1319–1326, 2002.

[59] W. Rahman, R. Suzuki, M. Webber, S. P. Hunt, and A. H. Dickenson, "Depletion of endogenous spinal 5-HT attenuates the behavioural hypersensitivity to mechanical and cooling stimuli induced by spinal nerve ligation," *Pain*, vol. 123, no. 3, pp. 264–274, 2006.

[60] A. Pertovaara, "Noradrenergic pain modulation," *Progress in Neurobiology*, vol. 80, no. 2, pp. 53–83, 2006.

[61] S. M. Walker, K. K. Tochiki, and M. Fitzgerald, "Hindpaw incision in early life increases the hyperalgesic response to repeat surgical injury: critical period and dependence on initial afferent activity," *Pain*, vol. 147, no. 1–3, pp. 99–106, 2009.

[62] E. Walter-Nicolet, D. Annequin, V. Biran, D. Mitanchez, and B. Tournaire, "Pain management in newborns: from prevention to treatment," *Pediatric Drugs*, vol. 12, no. 6, pp. 353–365, 2010.

[63] S. Gibbins, B. Stevens, E. Hodnett, J. Pinelli, A. Ohlsson, and G. Darlington, "Efficacy and safety of sucrose for procedural pain relief in preterm and term neonates," *Nursing Research*, vol. 51, no. 6, pp. 375–382, 2002.

[64] R. Slater, L. Cornelissen, L. Fabrizi et al., "Oral sucrose as an analgesic drug for procedural pain in newborn infants: a randomised controlled trial," *The Lancet*, vol. 376, no. 9748, pp. 1225–1232, 2010.

[65] R. Bellù, K. A. de Waal, and R. Zanini, "Opioids for neonates receiving mechanical ventilation," *Cochrane Database of Systematic Reviews*, no. 1, Article ID CD004212, 2008.

[66] R. E. Grunau, L. Holsti, and J. W. B. Peters, "Long-term consequences of pain in human neonates," *Seminars in Fetal and Neonatal Medicine*, vol. 11, no. 4, pp. 268–275, 2006.

[67] L. Holsti, J. Weinberg, M. F. Whitfield, and R. E. Grunau, "Relationships between adrenocorticotropic hormone and cortisol are altered during clustered nursing care in preterm infants born at extremely low gestational age," *Early Human Development*, vol. 83, no. 5, pp. 341–348, 2007.

[68] G. A. McCain and K. S. Tilbe, "Diurnal hormone variation in fibromyalgia syndrome: a comparison with rheumatoid arthritis," *Journal of Rheumatology*, vol. 16, supplement 19, pp. 154–157, 1989.

[69] E. N. Grieb, J. W. Boersma, and E. R. De Kloe, "Altered reactivity of the hypothalamic-pituitary-adrenal axis in the primary fibromyalgia syndrome," *Journal of Rheumatology*, vol. 20, no. 3, pp. 469–474, 1993.

[70] L. J. Crofford, S. R. Pillemmer, K. T. Kalogeras et al., "Hypothalamic-pituitary-adrenal axis perturbations in patients with fibromyalgia," *Arthritis and Rheumatism*, vol. 37, no. 11, pp. 1583–1592, 1994.

[71] D. Catley, A. T. Kaell, C. Kirschbaum, and A. A. Stone, "A naturalistic evaluation of cortisol secretion in persons with fibromyalgia and rheumatoid arthritis," *Arthritis Care and Research*, vol. 13, no. 1, pp. 51–61, 2000.

[72] E. Fries, J. Hesse, J. Hellhammer, and D. H. Hellhammer, "A new view on hypocortisolism," *Psychoneuroendocrinology*, vol. 30, no. 10, pp. 1010–1016, 2005.

[73] L. J. Crofford, E. A. Young, N. C. Engleberg et al., "Basal circadian and pulsatile ACTH and cortisol secretion in patients with fibromyalgia and/or chronic fatigue syndrome," *Brain, Behavior, and Immunity*, vol. 18, no. 4, pp. 314–325, 2004.
[74] B. S. McEwen and E. Stellar, “Stress and the individual: mechanisms leading to disease,” *Archives of Internal Medicine*, vol. 153, no. 18, pp. 2093–2101, 1993.

[75] E. F. Fernandez, R. Montman, and K. L. Watterberg, “ACTH and cortisol response to critical illness in term and late preterm newborns,” *Journal of Perinatology*, vol. 28, no. 12, pp. 797–802, 2008.

[76] C. E. Hanna, L. D. Keith, M. A. Colasurdo et al., “Hypothalamic pituitary adrenal function in the extremely low birth weight infant,” *Journal of Clinical Endocrinology and Metabolism*, vol. 76, no. 2, pp. 384–387, 1993.

[77] R. E. Grunau, L. Holsti, D. W. Haley et al., “Neonatal procedural pain exposure predicts lower cortisol and behavioral reactivity in preterm infants in the NICU,” *Pain*, vol. 113, no. 3, pp. 293–300, 2005.

[78] R. E. Grunau, M. T. Tu, M. F. Whitfield et al., “Cortisol, behavior, and heart rate reactivity to immunization pain at 4 months corrected age in infants born very preterm,” *Clinical Journal of Pain*, vol. 26, no. 8, pp. 698–704, 2010.

[79] R. E. Grunau, J. Weinberg, and M. F. Whitfield, “Neonatal procedural pain and preterm infant cortisol response to novelty at 8 months,” *Pediatrics*, vol. 114, no. 1, pp. e77–e84, 2004.

[80] R. E. Grunau, D. W. Haley, M. F. Whitfield, J. Weinberg, W. Yu, and P. Thiessen, “Altered basal cortisol levels at 3, 6, 8 and 18 months in infants born at extremely low gestational age,” *Journal of Pediatrics*, vol. 150, no. 2, pp. 151–156, 2007.

[81] S. Brummelte, R. E. Grunau, A. Zaidman-Zait, J. Weinberg, D. Nordstokke, and I. L. Cepeda, “Cortisol levels in relation to maternal interaction and child internalizing behavior in preterm and full-term children at 18 months corrected age,” *Developmental Psychobiology*, vol. 53, no. 2, pp. 184–195, 2011.

[82] A. Buske-Kirschbaum, S. Krieger, C. Wilkes, W. Rauh, S. Weiss, and D. H. Hellhammer, “Hypothalamic-pituitary-adrenal axis function and the cellular immune response in former preterm children,” *Journal of Clinical Endocrinology and Metabolism*, vol. 92, no. 9, pp. 3429–3435, 2007.

[83] L. M. Welberg and J. R. Seckl, “Prenatal stress, glucocorticoids and the programming of the brain,” *Journal of Neuroendocrinology*, vol. 13, no. 2, pp. 113–128, 2001.

[84] I. Zohar and M. Weinstock, “Differential effect of prenatal stress on the expression of corticotrophin-releasing hormone and its receptors in the hypothalamus and amygdala in male and female rats,” *Journal of Neuroendocrinology*, vol. 23, no. 4, pp. 320–328, 2011.

[85] R. Karlsson, J. Kallio, J. Toppari, M. Scheinin, and P. Kero, “Antenatal and early postnatal dexamethasone treatment decreases cortisol secretion in preterm infants,” *Hormone Research*, vol. 53, no. 4, pp. 170–176, 2000.

[86] E. P. Davis, F. Waffarn, and C. A. Sandman, “Prenatal treatment with glucocorticoids sensitizes the hpa axis response to stress among full-term infants,” *Developmental Psychobiology*, vol. 53, no. 2, pp. 175–183, 2011.

[87] P. O. Klingmann, I. Kugler, T. S. Steffke, S. Bellingrath, B. M. Kudiela, and D. H. Hellhammer, “Sex-specific prenatal programming: a risk for fibromyalgia?” *Annals of the New York Academy of Sciences*, vol. 1148, pp. 446–455, 2008.

[88] S. T. DeKosky, A. J. Nonneman, and S. W. Scheff, “ Morphologic and behavioral effects of perinatal glucocorticoid administration,” *Physiology and Behavior*, vol. 29, no. 5, pp. 895–900, 1982.

[89] J. P. Vicedomini, A. J. Nonneman, S. T. DeKosky, and S. W. Scheff, “Perinatal glucocorticoids disrupt learning: a sexually dimorphic response,” *Physiology and Behavior*, vol. 36, no. 1, pp. 145–149, 1986.

[90] M. Fameli, E. Kitraki, and F. Stylianopoulou, “Effects of hyperactivity of the maternal hypothalamic-pituitary-adrenal (HPA) axis during pregnancy on the development of the HPA axis and brain monoamines of the offspring,” *International Journal of Developmental Neuroscience*, vol. 12, no. 7, pp. 651–659, 1994.

[91] K. Muneoka, M. Mikuni, T. Ogawa et al., “Prenatal dexamethasone exposure alters brain monoamine metabolism and adrenocortical response in rat offspring,” *American Journal of Physiology*, vol. 273, no. 5, pp. R1669–R1675, 1997.

[92] S. A. Ferguson and R. R. Holson, “Neonatal dexamethasone on day 7 causes mild hyperactivity and cerebellar stunting,” *Neurotoxicology and Teratology*, vol. 21, no. 1, pp. 71–76, 1999.

[93] S. A. Ferguson, M. G. Paule, and R. R. Holson, “Neonatal dexamethasone on Day 7 in rats causes behavioral alterations reflective of hippocampal, but not cerebellar, deficits,” *Neurotoxicology and Teratology*, vol. 23, no. 1, pp. 57–69, 2001.

[94] J. M. Glass, “Fibromyalgia and cognition,” *Journal of Clinical Psychiary*, vol. 69, supplement 2, pp. 20–24, 2008.

[95] A. Kuchinad, P. Schweinhardt, D. A. Seminowicz, P. B. Wood, B. A. Chizh, and M. C. Bushnell, “Accelerated brain gray matter loss in fibromyalgia patients: premature aging of the brain?” *Journal of Neuroscience*, vol. 27, no. 15, pp. 4004–4007, 2007.

[96] S. Johnson, C. Hollis, P. Kochhar, E. Hennessy, D. Wolke, and N. Marlow, “Psychiatric disorders in extremely preterm children: longitudinal finding at age 11 years in the EPICure study,” *Journal of the American Academy of Child and Adolescent Psychiatry*, vol. 49, no. 5, pp. 453–463, 2010.

[97] S. Johnson, E. Hennessy, R. Smith, R. Trikic, D. Wolke, and N. Marlow, “Academic attainment and special educational needs in extremely preterm children at 11 years of age: the EPICure study,” *Archives of Disease in Childhood*, vol. 94, no. 4, pp. F283–F289, 2009.

[98] A. T. Bhutta, M. A. Cleves, P. H. Casey, M. M. Cradock, and K. J. S. Anand, “Cognitive and behavioral outcomes of school-aged children who were born preterm: a meta-analysis,” *Journal of the American Medical Association*, vol. 288, no. 6, pp. 728–737, 2002.

[99] M. S. Indredavik, T. Vik, S. Heyerdahl, S. Kulseng, P. Fayers, and K. Muneoka, “Prenatal dexamethasone administration with glucocorticoids sensitizes the hpa axis response to stress among full-term infants,” *Archives of Disease in Childhood*, vol. 89, no. 5, pp. F445–F450, 2004.

[100] S. V. Desai, T. J. Law, and D. M. Needham, “Long-term complications of critical care,” *Critical Care Medicine*, vol. 39, no. 2, pp. 371–379, 2011.

[101] M. Ajayi-Obe, N. Saeed, F. M. Cowan, M. A. Rutherford, and P. H. Casey, “Reduced development of cerebral cortex in adolescents with low birth weight,” *Archives of Disease in Childhood*, vol. 94, no. 7, pp. 536–548, 2006.

[102] J. P. Boardman, S. J. Counsell, D. Rueckert et al., “Abnormal deep grey matter development following preterm birth
detected using deformation-based morphometry,” *Neurolmage*, vol. 32, no. 1, pp. 79–78, 2006.

[104] S. J. Counsell, L. E. Dyet, D. J. Larkman et al., “Thalamocortical connectivity in children born preterm mapped using probabilistic magnetic resonance tractography,” *Neurolmage*, vol. 34, no. 3, pp. 896–904, 2007.

[105] J. I. Berman, P. Mukherjee, S. C. Partridge et al., “Quantitative diffusion tensor MRI fiber tractography of sensorimotor white matter development in premature infants,” *Neurolmage*, vol. 27, no. 4, pp. 862–871, 2005.

[106] P. G. Croskerry, G. K. Smith, and M. Leon, “Thermoregulation and the maternal behaviour of the rat,” *Nature*, vol. 273, no. 5660, pp. 299–300, 1978.

[107] P. M. Plotksy and M. J. Meaney, “Early, postnatal experience alters hypothalamic corticotropin-releasing factor (CRF) mRNA, median eminence CRF content and stress-induced release in adult rats,” *Molecular Brain Research*, vol. 18, no. 3, pp. 195–203, 1993.

[108] P. M. Plotksy, K. V. Thrivikraman, C. B. Nemerooff, C. Caldji, S. Sharma, and M. J. Meaney, “Long-term consequences of neonatal rearing on central corticotropin-releasing factor systems in adult male rat offspring,” *Neuropsychopharmacology*, vol. 30, no. 12, pp. 2192–2204, 2005.

[109] C. Caldji, D. Francis, S. Sharma, P. M. Plotksy, and M. J. Meaney, “The effects of early rearing environment on the development of GABA(A) and central benzodiazepine receptor levels and novelty-induced fearfulness in the rat,” *Neuropsychopharmacology*, vol. 22, no. 3, pp. 219–229, 2000.

[110] R. L. Huot, K. V. Thrivikraman, M. J. Meaney, and P. M. Plotksy, “Development of adult ethanol preference and anxiety as a consequence of neonatal maternal separation in Long Evans rats and reversal with antidepressant treatment,” *Psychopharmacology*, vol. 158, no. 4, pp. 366–373, 2001.

[111] W. M. U. Daniels, C. Y. Pietersen, M. E. Carstens, and D. J. Stein, “Maternal separation in rats leads to anxiety-like behavior and a blunted ACTH response and altered neurotransmitter levels in response to a subsequent stressor,” *Metabolic Brain Disease*, vol. 19, no. 1-2, pp. 3–14, 2004.

[112] K. Matthews and T. W. Robbins, “Early experience as a determinant of adult behavioural responses to reward: the effects of repeated maternal separation in the rat,” *Neuroscience and Biobehavioral Reviews*, vol. 27, no. 1-2, pp. 45–55, 2003.

[113] B. A. Ellenbroek and M. A. Riva, “Early maternal deprivation as an animal model for schizophrenia,” *Clinical Neuroscience Research*, vol. 3, no. 4-5, pp. 297–302, 2003.

[114] M. L. Uhelski and P. N. Fuchs, “Maternal separation stress leads to enhanced emotional responses to noxious stimuli in adult rats,” *Behavioural Brain Research*, vol. 212, no. 2, pp. 208–212, 2010.

[115] C. Fahlke, J. G. Lorenz, J. Long, M. Champoux, S. J. Suomi, and J. D. Higley, “Rearing experiences and stress-induced plasma cortisol as early risk factors for excessive alcohol consumption in nonhuman primates,” *Alcoholism*, vol. 24, no. 5, pp. 644–650, 2000.

[116] L. A. Bradley, “Pathophysiology of fibromyalgia,” *American Journal of Medicine*, vol. 122, no. 12, pp. S22–S30, 2009.

[117] M. J. Meaney, D. H. Aitken, and S. R. Bodnoff, “The effects of postnatal handling on the development of the glucocorticoid receptor systems and stress recovery in the rat,” *Progress in Neuro-Psychopharmacology and Biological Psychiatry*, vol. 9, no. 3-6, pp. 731–734, 1985.

[118] M. J. Meaney, D. H. Aitken, C. Van Berkel, S. Bhatnagar, and R. M. Sapolsky, “Effect of neonatal handling on age-related impairments associated with the hippocampus,” *Science*, vol. 239, no. 4841, pp. 766–768, 1988.

[119] M. J. Meaney, D. H. Aitken, S. Bhatnagar, and R. M. Sapolsky, “Postnatal handling attenuates certain neuroendocrine, anatomical, and cognitive dysfunctions associated with aging in female rats,” *Neurobiology of Aging*, vol. 12, no. 1, pp. 31–38, 1991.

[120] C. R. Pryce, D. Bettschen, N. I. Bahr, and J. Feldon, “Comparison of the effects of infant handling, isolation, and nonhandling on acoustic startle, prepulse inhibition, locomotion, and HPA activity in the adult rat,” *Behavioral Neuroscience*, vol. 115, no. 1, pp. 71–83, 2001.

[121] C. O. Ladd, R. L. Huot, K. V. Thrivikraman, C. B. Nemerooff, M. J. Meaney, and P. M. Plotksy, “Long-term behavioral and neuroendocrine adaptations to adverse early experience,” *Progress in Brain Research*, vol. 122, pp. 81–103, 2000.

[122] D. Liu, J. Diorio, B. Tannenbaum et al., “Maternal care, hippocampal glucocorticoid receptors, and hypothalamic-pituitary-adrenal responses to stress,” *Science*, vol. 277, no. 5332, pp. 1659–1662, 1997.

[123] C. R. Pryce, D. Bettschen, and J. Feldon, “Comparison of the effects of early handling and early deprivation on maternal care in the rat,” *Developmental Psychobiology*, vol. 38, no. 4, pp. 239–251, 2001.

[124] C. Caldji, B. Tannenbaum, S. Sharma, D. Francis, P. M. Plotksy, and M. J. Meaney, “Maternal care during infancy regulates the development of neural systems mediating the expression of fearfulness in the rat,” *Proceedings of the National Academy of Sciences of the United States of America*, vol. 95, no. 9, pp. 5335–5340, 1998.

[125] D. Francis, J. Diorio, D. Liu, and M. J. Meaney, “Nongenomic transmission across generations of maternal behavior and stress responses in the rat,” *Science*, vol. 286, no. 5442, pp. 1155–1158, 1999.

[126] F. A. Champagne and M. J. Meaney, “Transgenerational effects of social environment on variations in maternal care and behavioral response to novelty,” *Behavioral Neuroscience*, vol. 121, no. 6, pp. 1333–1363, 2007.

[127] D. Liu, J. Diorio, J. C. Day, D. D. Francis, and M. J. Meaney, “Maternal care, hippocampal synaptogenesis and cognitive development in rats,” *Nature Neuroscience*, vol. 3, no. 8, pp. 799–806, 2000.

[128] G. Rentesi, K. Antoniou, M. Marselos, A. Fotopoulos, J. Albooycharali, and M. Konstandi, “Long-term consequences of early maternal deprivation in serotoninergic activity and HPA function in adult rat,” *Neuroscience Letters*, vol. 480, no. 1, pp. 7–11, 2010.

[129] S. Orelan, C. Pickering, C. Gök turk, L. Orelan, L. Arborelius, and J. Nylander, “Two repeated maternal separation procedures differentially affect brain 5-hydroxytryptamine transporter and receptors in young and adult male and female rats,” *Brain Research*, vol. 1305, pp. S37–S49, 2009.

[130] A. Vicentic, D. Francis, M. Moffett et al., “Maternal separation alters serotoninergic transporter densities and serotoninergic 1A receptors in rat brain,” *Neuroscience*, vol. 140, no. 1, pp. 355–365, 2006.

[131] M. F. Seidel and W. Müller, “Differential pharmacotherapy for subgroups of fibromyalgia patients with specific consideration of 5-HT3 receptor antagonists,” *Expert Opinion on Pharmacotherapy*, vol. 12, no. 9, pp. 1381–1391, 2011.
[132] M. Offenbaecher, B. Bondy, S. De Jonge et al., “Possible association of fibromyalgia with a polymorphism in the serotonin transporter gene regulatory region,” Arthritis and Rheumatism, vol. 42, no. 11, pp. 2482–2488, 1999.

[133] E. Paul-Savoie, S. Potvin, K. Daigle et al., “A deficit in peripheral serotonin levels in major depressive disorder but not in chronic widespread pain,” Clinical Journal of Pain, vol. 27, no. 6, pp. 529–534, 2011.

[134] J. Bowlby, “The nature of the child’s tie to his mother,” The International Journal of Psycho-Analysis, vol. 39, no. 5, pp. 350–373, 1958.

[135] J. Bowlby, “Attachment theory and its therapeutic implications,” Adolescent Psychiatry, vol. 6, pp. 5–33, 1978.

[136] L. S. Porter, D. Davis, and F. J. Keefe, “Attachment and pain: recent findings and future directions,” Pain, vol. 128, no. 3, pp. 195–198, 2007.

[137] P. Ciechanowski, M. Sullivan, M. Jensen, J. Romano, and H. Summers, “The relationship of attachment style to depression, catastrophizing and health care utilization in patients with chronic pain,” Pain, vol. 104, no. 3, pp. 627–637, 2003.

[138] P. Meredith, J. Strong, and J. A. Feeney, “Adult attachment, anxiety, and pain self-efficacy as predictors of pain intensity and disability,” Pain, vol. 123, no. 1-2, pp. 146–154, 2006.

[139] P. J. Meredith, J. Strong, and J. A. Feeney, “The relationship of adult attachment to emotion, catastrophizing, control, threshold and tolerance, in experimentally-induced pain,” Pain, vol. 120, no. 1-2, pp. 44–52, 2006.

[140] T. R. Insel, “Is social attachment an addictive disorder?” Physiology and Behavior, vol. 79, no. 3, pp. 351–357, 2003.

[141] A. Moles, B. L. Kieffer, and F. R. D’Amato, “Deficit in attachment behavior in mice lacking the μ-opioid receptor gene,” Science, vol. 304, no. 5679, pp. 1983–1986, 2004.

[142] L. R. M. Hallberg and S. G. Carlsson, “Psychosocial vulnerability and maintaining forces related to fibromyalgia: in-depth interviews with twenty-two female patients,” Scandinavian Journal of Caring Sciences, vol. 12, no. 2, pp. 95–103, 1998.

[143] E. A. Walker, D. Keegan, G. Gardner, M. Sullivan, D. Bernstein, and W. I. Katon, “Psychosocial factors in fibromyalgia compared with rheumatoid arthritis: II. Sexual, physical, and emotional abuse and neglect,” Psychosomatic Medicine, vol. 59, no. 6, pp. 572–577, 1997.

[144] R. W. Alexander, L. A. Bradley, G. S. Alarcón et al., “Sexual and physical abuse in women with fibromyalgia: association with outpatient health care utilization and pain medication usage,” Arthritis Care and Research, vol. 11, no. 2, pp. 102–115, 1998.

[145] J. McBeth, G. J. Macfarlane, S. Benjamin, S. Morris, and A. J. Silman, “The association between tender points, psychological distress, and adverse childhood experiences: a community based study,” Arthritis and Rheumatism, vol. 42, no. 7, pp. 1397–1404, 1999.

[146] B. Van Houdenhove, E. Neerinckx, R. Lysens et al., “Victimization in chronic fatigue syndrome and fibromyalgia in tertiary care: a controlled study on prevalence and characteristics,” Psychosomatics, vol. 42, no. 1, pp. 21–28, 2001.

[147] M. L. Paras, M. H. Murad, L. P. Chen et al., “Sexual abuse and lifetime diagnosis of somatic disorders: a systematic review and meta-analysis,” Journal of the American Medical Association, vol. 302, no. 5, pp. 550–561, 2009.

[148] W. Häuser, M. Kosseva, N. Üceyler, P. Klose, and C. Sommer, “Emotional, physical, and sexual abuse in fibromyalgia syndrome: a systematic review with meta-analysis,” Arthritis Care and Research, vol. 63, no. 6, pp. 808–820, 2011.

[149] V. J. Felitti, R. F. Anda, D. Nordenberg et al., “Relationship of childhood abuse and household dysfunction to many of the leading causes of death in adults: the adverse childhood experiences (ACE) study,” American Journal of Preventive Medicine, vol. 14, no. 4, pp. 245–258, 1998.

[150] B. S. McEwen, “Understanding the potency of stressful early life experiences on brain and body function,” Metabolism, vol. 57, no. 2, pp. S11–S15, 2008.

[151] H. Steiger, L. Gauvin, M. Israël et al., “Association of serotonin and cortisol indices with childhood abuse in bulimia nervosa,” Archives of General Psychiatry, vol. 58, no. 9, pp. 837–843, 2001.

[152] J. Kim-Cohen, A. Caspi, A. Taylor et al., “MAOA, maltreatment, and gene-environment interaction predicting children’s mental health: new evidence and a meta-analysis,” Molecular Psychiatry, vol. 11, no. 10, pp. 903–913, 2006.

[153] K. Ritchie, I. Jaussent, R. Stewart et al., “Association of adverse childhood environment and 5-HTTLPR genotype with late-life depression,” Journal of Clinical Psychiatry, vol. 70, no. 9, pp. 1281–1288, 2009.

[154] J. M. Miller, E. L. Kninnally, R. T. Ogden, M. A. Oquendo, J. J. Mann, and R. V. Parsey, “Reported childhood abuse is associated with low serotonin transporter binding in vivo in major depressive disorder,” Synapse, vol. 63, no. 7, pp. 565–573, 2009.

[155] R. Tikkanen, F. Ducci, D. Goldman et al., “MAOA alters the effects of heavy drinking and childhood physical abuse on risk for severe impulsive acts of violence among alcoholic violent offenders,” Alcoholism, vol. 34, no. 5, pp. 853–860, 2010.

[156] R. T. Goldberg, W. N. Pachas, and D. Keith, “Relationship between traumatic events in childhood and chronic pain,” Disability and Rehabilitation, vol. 21, no. 1, pp. 23–30, 1999.

[157] U. M. Anderberg, I. Marteinsdottir, T. Theorell, and L. Von Knorring, “The impact of life events in female patients with fibromyalgia and in female healthy controls,” European Psychiatry, vol. 15, no. 5, pp. 295–301, 2000.

[158] N. A. Nicolson, M. C. Davis, D. Kruszewski, and A. J. Zautra, “Childhood maltreatment and diurnal cortisol patterns in women with chronic pain,” Psychosomatic Medicine, vol. 72, no. 5, pp. 471–480, 2010.

[159] N. A. Nicolson, “Childhood parental loss and cortisol levels in adult men,” Psychoneuroendocrinology, vol. 29, no. 8, pp. 1012–1018, 2004.

[160] A. R. Tyrka, L. Wier, L. H. Price et al., “Childhood parental loss and adult hypothalamic-pituitary-adrenal function,” Biological Psychiatry, vol. 63, no. 12, pp. 1147–1154, 2008.

[161] L. J. Lucock, “Childhood attachment and loss experiences affect adult cardiovascular and cortisol function,” Psychosomatic Medicine, vol. 60, no. 6, pp. 765–772, 1998.

[162] L. L. Carpenter, A. R. Tyrka, C. J. McDougle et al., “Cerebrospinal fluid corticotropin-releasing factor and perceived early-life stress in depressed patients and healthy control subjects,” Neuropsychopharmacology, vol. 29, no. 4, pp. 777–784, 2004.

[163] A. Danese, C. M. Pariente, A. Caspi, A. Taylor, and R. Poulton, “Childhood maltreatment predicts adult inflammation
in a life-course study,” *Proceedings of the National Academy of Sciences of the United States of America*, vol. 104, no. 4, pp. 1319–1324, 2007.

[164] S. A. McLean, D. A. Williams, P. K. Stein et al., “Cerebrospinal fluid corticotropin-releasing factor concentration is associated with pain but not fatigue symptoms in patients with fibromyalgia,” *Neuropsychopharmacology*, vol. 31, no. 12, pp. 2776–2782, 2006.

[165] I. Weissbecker, A. Floyd, E. Dedert, P. Salmon, and S. Septon, “Childhood trauma and diurnal cortisol disruption in fibromyalgia syndrome,” *Psychoneuroendocrinology*, vol. 31, no. 3, pp. 312–324, 2006.

[166] L. R. M. Hallberg and S. G. Carlsson, “Coping with fibromyalgia—a qualitative study,” *Scandinavian Journal of Caring Sciences*, vol. 14, no. 1, pp. 29–36, 2000.

[167] J. McBeth, S. Morris, S. Benjamin, A. J. Silman, and G. J. Macfarlane, “Associations between adverse events in childhood and chronic widespread pain in adulthood: are they explained by differential recall?” *Journal of Rheumatology*, vol. 28, no. 10, pp. 2305–2309, 2001.

[168] C. Power, K. Atherton, D. P. Strachan et al., “Life-course influences on health in British adults: effects of socioeconomic position in childhood and adulthood,” *International Journal of Epidemiology*, vol. 36, no. 3, pp. 532–539, 2007.

[169] M. O’Donnell, N. Nassar, H. Leonard, R. Mathews, Y. J. McBeth, S. Morris, S. Benjamin, A. J. Silman, and G. J. Macfarlane, “Associations between adverse events in childhood and chronic widespread pain in adulthood: are they explained by differential recall?” *Journal of Rheumatology*, vol. 28, no. 10, pp. 2305–2309, 2001.

[170] A. Jud, U. Lips, and M. A. Landolt, “Characteristics associated with maltreatment types in children referred to a hospital protection team,” *European Journal of Pediatrics*, vol. 169, no. 2, pp. 173–180, 2010.

[171] S. Howell, N. J. Talley, S. Quine, and R. Poulton, “The irritable bowel syndrome has origins in the childhood socioeconomic environment,” *American Journal of Gastroenterology*, vol. 99, no. 8, pp. 1572–1578, 2004.

[172] E. L. Rangel, R. S. Burd, and R. A. Falcone Jr., “Socioeconomic disparities in infant mortality after nonaccidental trauma: a multicenter study,” *Journal of Trauma*, vol. 69, no. 1, pp. 20–25, 2010.

[173] P. B. Wood, P. Schweinhardt, E. Jaeger et al., “Fibromyalgia patients show an abnormal dopaminergic response to pain,” *European Journal of Neuroscience*, vol. 25, no. 12, pp. 3576–3582, 2007.

[174] J. N. Baraniuk, G. Whalen, J. Cunningham, and D. J. Clauw, “Cerebrospinal fluid levels of opioid peptides in fibromyalgia and chronic low back pain,” *BMC Musculoskeletal Disorders*, vol. 5, article 48, 2004.

[175] R. E. Harris, D. J. Clauw, D. J. Scott, S. A. McLean, R. H. Gracely, and J. K. Zubieta, “Decreased central µ-opioid receptor availability in fibromyalgia,” *Journal of Neuroscience*, vol. 27, no. 37, pp. 10000–10006, 2007.

[176] M. J. Druse, N. Tajuddin, A. Kuo, and M. Connerty, “Effects of in utero ethanol exposure on the developing dopaminergic system in rats,” *Journal of Neuroscience Research*, vol. 27, no. 2, pp. 233–240, 1990.

[177] M. J. Druse, A. Kuo, and N. Tajuddin, “Effects of in utero ethanol exposure on the developing serotonergic system,” *Alcoholism*, vol. 15, no. 4, pp. 678–684, 1991.

[178] X. Zhang, J. H. Sliwowska, and J. Weinberg, “Prenatal alcohol exposure and fetal programming: effects on neuroendocrine and immune function,” *Experimental Biology and Medicine*, vol. 230, no. 6, pp. 376–388, 2005.

[179] L. P. Finnegan, J. F. Connaughton, R. E. Kron, and J. P. Emich, “Neonatal abstinence syndrome: assessment and management,” *Addictive Diseases*, vol. 2, no. 1–2, pp. 141–158, 1975.

[180] K. L. Jones and G. A. Barr, “Ontogeny of morphine withdrawal in the rat,” *Behavioral Neuroscience*, vol. 109, no. 6, pp. 1189–1198, 1995.

[181] J. C. Rozé, S. Denizot, R. Carbajal et al., “Prolonged sedation and/or analgesia and 5-year neurodevelopment outcome in very preterm infants: results from the EPIPAGE cohort,” *Archives of Pediatrics and Adolescent Medicine*, vol. 162, no. 8, pp. 728–733, 2008.

[182] A. Tempel, J. Habas, W. Paredes, and G. A. Barr, “Morphine-induced downregulation of mu-opioid receptors in neonatal rat brain,” *Brain Research*, vol. 469, no. 1–2, pp. 129–133, 1988.

[183] S. R. Thornton and F. L. Smith, “Long-term alterations in opiate antinociception resulting from infant fentanyl tolerance and dependence,” *European Journal of Pharmacology*, vol. 363, no. 2–3, pp. 113–119, 1998.

[184] R. E. Harris, J. K. Zubieta, D. J. Scott, V. Napadow, R. H. Gracely, and D. J. Clauw, “Traditional Chinese acupuncture and placebo (sham) acupuncture are differentiated by their effects on µ-opioid receptors (MORs),” *Neuralmage*, vol. 47, no. 3, pp. 1077–1085, 2009.

[185] T. Sithisarn, H. S. Bada, H. Dai, D. C. Randall, and S. J. Legan, “Effects of perinatal cocaine exposure on open field behavior and the response to corticotropin releasing hormone (CRH) in rat offspring,” *Brain Research*, vol. 1370, pp. 136–144, 2011.

[186] G. Battaglia and T. M. Cabrera, “Potentiation of 5-HT(1A) receptor-mediated neuroendocrine responses in male but not female rat progeny after prenatal cocaine: evidence for gender differences,” *Journal of Pharmacology and Experimental Therapeutics*, vol. 271, no. 3, pp. 1453–1461, 1994.

[187] F. Roussotte, L. Soderberg, and E. Sowell, “Structural, metabolic, and functional brain abnormalities as a result of prenatal exposure to drugs of abuse: evidence from neuroimaging,” *Neuropsychology Review*, vol. 20, no. 4, pp. 376–397, 2010.

[188] F. I. Tarazi and R. J. Baldessarini, “Comparative postnatal development of dopamine D1, D2 and D4 receptors in rat foerebrain,” *International Journal of Developmental Neuroscience*, vol. 18, no. 1, pp. 29–37, 2000.

[189] P. B. Wood, “Mesolimbic dopaminergic mechanisms and pain control,” *Pain*, vol. 120, no. 3, pp. 230–234, 2006.

[190] P. B. Wood, “Mesolimbic dopaminergic mechanisms and pain control,” *Pain*, vol. 120, no. 3, pp. 230–234, 2006.

[191] P. B. Wood, M. F. Glabus, R. Simpson, and J. C. Patterson II, “Changes in gray matter density in fibromyalgia: correlation with pain control,” *NeuroImage*, vol. 47, pp. 2776–2782, 2010.

[192] S. Gürsoy, E. Erdal, H. Herken, E. Madenci, B. Alaşehrili, and N. Erdal, “Significance of catechol-O-methyltransferase gene polymorphism in fibromyalgia syndrome,” *Rheumatology International*, vol. 23, no. 3, pp. 104–107, 2003.

[193] D. Buskila, H. Cohen, L. Neuman, and R. P. Ebstein, “An association between fibromyalgia and the dopamine D4 receptor availability in fibromyalgia,” *Journal of Neuroscience*, vol. 23, no. 3, pp. 1048–1055, 2003.

[194] V. L. Meador, P. S. Resnick, and S. E. Davis, “The relationship of postpartum fibromyalgia with related maternal and infant outcomes,” *Journal of Obstetric, Gynecologic, and Neonatal Nursing*, vol. 32, no. 6, pp. 701–709, 2003.

[195] R. P. Wood, “The role of dopaminergic systems in the pathogenesis of fibromyalgia,” *Brain Research*, vol. 623, no. 1–2, pp. 17–25, 1993.
receptor exon III repeat polymorphism and relationship to novelty seeking personality traits," *Molecular Psychiatry*, vol. 9, no. 8, pp. 730–731, 2004.

[194] M. H. Boisset-Pioro, J. M. Esdaile, and M. A. Fitzcharles, "Sexual and physical abuse in women with fibromyalgia syndrome," *Arthritis and Rheumatism*, vol. 38, no. 2, pp. 235–241, 1995.

[195] K. Imbierowicz and U. T. Egle, “Childhood adversities in patients with fibromyalgia and somatoform pain disorder,” *European Journal of Pain*, vol. 7, no. 2, pp. 113–119, 2003.